157 related articles for article (PubMed ID: 22381179)
1. Management of attention-deficit disorder and attention-deficit/hyperactivity disorder drug intoxication in dogs and cats.
Stern LA; Schell M
Vet Clin North Am Small Anim Pract; 2012 Mar; 42(2):279-87, vi. PubMed ID: 22381179
[TBL] [Abstract][Full Text] [Related]
2. Management of Attention-Deficit Disorder and Attention-Deficit/Hyperactivity Disorder Drug Intoxication in Dogs and Cats: An Update.
Stern L; Schell M
Vet Clin North Am Small Anim Pract; 2018 Nov; 48(6):959-968. PubMed ID: 30172446
[TBL] [Abstract][Full Text] [Related]
3. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity.
Lovecchio F; Kashani J
J Emerg Med; 2006 Oct; 31(3):267-8. PubMed ID: 16982359
[TBL] [Abstract][Full Text] [Related]
4. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
9. Adderall® (amphetamine-dextroamphetamine) toxicity.
Fitzgerald KT; Bronstein AC
Top Companion Anim Med; 2013 Feb; 28(1):2-7. PubMed ID: 23796480
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
[TBL] [Abstract][Full Text] [Related]
12. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
13. Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats.
Khan SA; McLean MK
Vet Clin North Am Small Anim Pract; 2012 Mar; 42(2):289-306, vi-vii. PubMed ID: 22381180
[TBL] [Abstract][Full Text] [Related]
14. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
Kaplan G; Newcorn JH
Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
[TBL] [Abstract][Full Text] [Related]
16. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
[TBL] [Abstract][Full Text] [Related]
17. Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment.
Sangal RB; Sangal JM
Expert Rev Neurother; 2006 Oct; 6(10):1429-37. PubMed ID: 17078784
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Eiland LS; Guest AL
Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
[TBL] [Abstract][Full Text] [Related]
19. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R; Hodgkins P; Meijer W
Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
[TBL] [Abstract][Full Text] [Related]
20. [Drugs for attention deficit hyperactivity disorder].
Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
